Chronic Kidney Disease

The Lancet

Volumn 389, Issue 10075, 2017, Pages 1238-1252

  Webster, Angela C ^a,b   Nagler, Evi V ^c   Morton, Rachael L ^d   Masson, Philip ^e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; UREMIC TOXIN;

ANEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; COGNITION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ECHOGRAPHY; ESTIMATED GLOMERULAR FILTRATION RATE; FUNDING; HEALTH CARE ACCESS; HEALTH CARE FINANCING; HEALTH EQUITY; HEALTH LITERACY; HEALTH SERVICE; HEMATURIA; HISTOPATHOLOGY; HUMAN; IMAGE GUIDED BIOPSY; KIDNEY BIOPSY; KIDNEY INJURY; KIDNEY TRANSPLANTATION; MALIGNANT NEOPLASM; META ANALYSIS (TOPIC); PATHOPHYSIOLOGY; PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; PYURIA; QUALITY OF LIFE; REIMBURSEMENT; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); URINE SEDIMENT; DISEASE EXACERBATION; GENETIC PREDISPOSITION; GLOMERULUS FILTRATION RATE; KIDNEY; PATHOLOGY; PROCEDURES;

DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GLOMERULAR FILTRATION RATE; HUMANS; IMAGE-GUIDED BIOPSY; KIDNEY; PROGNOSIS; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 85007246687     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)32064-5     Document Type: Review

References (102)

1. 1 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl, 2013, 1–150.
2. 2 World Health Organization. Mortality and global health estimates: Causes of death; Projections for 2015–2030; Projection of death rates. http://apps.who.int/gho/data/node.main.PROJRATEWORLD?lang=en (accessed 29 June, 2016).
3. 3 Morton, RL, Schlackow, I, Mihaylova, B, Staplin, ND, Gray, A, Cass, A, The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review. Nephrol Dial Transplant 31 (2016), 46–56.
4. 4 Hildebrandt, F, Genetic kidney diseases. Lancet 375 (2010), 1287–1295.
5. 5 Smyth, LJ, Duffy, S, Maxwell, AP, McKnight, AJ, Genetic and epigenetic factors influencing chronic kidney disease. Am J Physiol Renal Physiol 307 (2014), F757–F776.
6. 6 Reddy, MA, Natarajan, R, Recent developments in epigenetics of acute and chronic kidney diseases. Kidney Int 88 (2015), 250–261.
7. 7 Dwivedi, RS, Herman, JG, McCaffrey, TA, Raj, DS, Beyond genetics: epigenetic code in chronic kidney disease. Kidney Int 79 (2011), 23–32.
8. 8 Anders, HJ, Andersen, K, Stecher, B, The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 83 (2013), 1010–1016.
9. 9 Vanholder, R, Baurmeister, U, Brunet, P, Cohen, G, Glorieux, G, Jankowski, J, A bench to bedside view of uremic toxins. J Am Soc Nephrol 19 (2008), 863–870.
10. 10 Lisowska-Myjak, B, Uremic toxins and their effects on multiple organ systems. Nephron Clin Pract 128 (2014), 303–311.
11. 11 Eloot, S, Schepers, E, Barreto, DV, et al. Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins. Clin J Am Soc Nephrol 6 (2011), 1266–1273.
12. 12 Levey, AS, Becker, C, Inker, LA, Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA 313 (2015), 837–846.
13. 13 Garasto, S, Fusco, S, Corica, F, et al. Estimating glomerular filtration rate in older people. Biomed Res Int, 2014, 2014, 916542.
14. 14 Lamb, EJ, Stevens, PE, Estimating and measuring glomerular filtration rate: methods of measurement and markers for estimation. Curr Opin Nephrol Hypertens 23 (2014), 258–266.
15. 15 Soveri, I, Berg, UB, Björk, J, et al. Measuring GFR: a systematic review. Am J Kidney Dis 64 (2014), 411–424.
16. 16 Earley, A, Miskulin, D, Lamb, EJ, Levey, AS, Uhlig, K, Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 156 (2012), 785–795.
17. 17 Hoste, L, Deiteren, K, Pottel, H, Callewaert, N, Martens, F, Routine serum creatinine measurements: how well do we perform?. BMC Nephrol, 16, 2015, 21.
18. 18 Inker, LA, Levey, AS, Pandya, K, Stoycheff, N, Okparavero, A, Greene, T, Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis 64 (2014), 74–85.
19. 19 Martin, H, Laboratory measurement of urine albumin and urine total protein in screening for proteinuria in chronic kidney disease. Clin Biochem Rev 32 (2011), 97–102.
20. 20 Wu, HY, Peng, YS, Chiang, CK, et al. Diagnostic performance of random urine samples using albumin concentration vs ratio of albumin to creatinine for microalbuminuria screening in patients with diabetes mellitus: a systematic review and meta-analysis. JAMA Intern Med 174 (2014), 1108–1115.
21. 21 McTaggart, MP, Newall, RG, Hirst, JA, et al. Diagnostic accuracy of point-of-care tests for detecting albuminuria: a systematic review and meta-analysis. Ann Intern Med 160 (2014), 550–557.
22. 22 Perazella, MA, The urine sediment as a biomarker of kidney disease. Am J Kidney Dis 66 (2015), 748–755.
23. 23 Remer, EM, Papanicolaou, N, Casalino, DD, et al. ACR appropriateness criteria® on renal failure. Am J Med 127 (2014), 1041–1048.
24. 24 Corapi, KM, Chen, JL, Balk, EM, Gordon, CE, Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis 60 (2012), 62–73.
25. 25 Hogan, JJ, Mocanu, M, Berns, JS, The native kidney biopsy: update and evidence for best practice. Clin J Am Soc Nephrol 11 (2016), 354–362.
26. 26 Tangri, N, Kitsios, GD, Inker, LA, et al. Risk prediction models for patients with chronic kidney disease: a systematic review. Ann Intern Med 158 (2013), 596–603.
27. 27 Keith, DS, Nichols, GA, Gullion, CM, Brown, JB, Smith, DH, Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164 (2004), 659–663.
28. 28 US Renal Data System. USRDS 2012 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States, 2012, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
29. 29 Tonelli, M, Wiebe, N, Culleton, B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17 (2006), 2034–2047.
30. 30 Thompson, S, James, M, Wiebe, N, et al. Cause of death in patients with reduced kidney function. J Am Soc Nephrol 26 (2015), 2504–2511.
31. 31 Lefebvre, P, Vekeman, F, Sarokhan, B, Enny, C, Provenzano, R, Cremieux, PY, Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin 22 (2006), 1929–1937.
32. 32 Locatelli, F, Pisoni, RL, Combe, C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19 (2004), 121–132.
33. 33 Palmer, SC, Navaneethan, SD, Craig, JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 153 (2010), 23–33.
34. 34 Silverberg, DS, Iaina, A, Peer, G, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27 (1996), 234–238.
35. 35 Rozen-Zvi, B, Gafter-Gvili, A, Paul, M, Leibovici, L, Shpilberg, O, Gafter, U, Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 52 (2008), 897–906.
36. 36 Coen, G, Ballanti, P, Bonucci, E, et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron 91 (2002), 103–111.
37. 37 Alem, AM, Sherrard, DJ, Gillen, DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58 (2000), 396–399.
38. 38 Di Leo, C, Gallieni, M, Bestetti, A, et al. Cardiac and pulmonary calcification in a hemodialysis patient: partial regression 4 years after parathyroidectomy. Clin Nephrol 59 (2003), 59–63.
39. 39 Silver, J, Naveh-Many, T, FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nat Rev Nephrol 9 (2013), 641–649.
40. 40 Kidney Disease Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int Suppl 76 (2009), S1–S130.
41. 41 Navaneethan, SD, Palmer, SC, Vecchio, M, Craig, JC, Elder, GJ, Strippoli, GF, Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev, 2, 2011 CD006023.
42. 42 Palmer, SC, McGregor, DO, Craig, JC, Elder, G, Macaskill, P, Strippoli, GF, Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev, 4, 2009 CD005633.
43. 43 Di Angelantonio, E, Danesh, J, Eiriksdottir, G, Gudnason, V, Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. PLoS Med, 4, 2007, e270.
44. 44 Perkovic, V, Verdon, C, Ninomiya, T, et al. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med, 5, 2008, e207.
45. 45 Matsushita, K, van der Velde, M, Astor, BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375 (2010), 2073–2081.
46. 46 Gansevoort, RT, Matsushita, K, van der Velde, M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 80 (2011), 93–104.
47. 47 Masson, P, Webster, AC, Hong, M, Turner, R, Lindley, RI, Craig, JC, Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. Nephrol Dial Transplant 30 (2015), 1162–1169.
48. 48 K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45:suppl 3 (2005), S1–153.
49. 49 Palmer, SC, Di Micco, L, Razavian, M, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev, 2, 2013 CD008834.
50. 50 Wanner, C, Tonelli, M, KDIGO Clinical Practice Guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 85 (2014), 1303–1309.
51. 51 Palmer, SC, Craig, JC, Navaneethan, SD, Tonelli, M, Pellegrini, F, Strippoli, GF, Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 157 (2012), 263–275.
52. 52 Chobanian, AV, Bakris, GL, Black, HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003), 2560–2572.
53. 53 Mancia, G, Laurent, S, Agabiti-Rosei, E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 27 (2009), 2121–2158.
54. 54 Lv, J, Ehteshami, P, Sarnak, MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 185 (2013), 949–957.
55. 55 Rashid, P, Leonardi-Bee, J, Bath, P, Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 34 (2003), 2741–2748.
56. 56 Sharma, P, Blackburn, RC, Parke, CL, McCullough, K, Marks, A, Black, C, Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev, 10, 2011 CD007751.
57. 57 Strippoli, GF, Bonifati, C, Craig, M, Navaneethan, SD, Craig, JC, Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev, 4, 2006 CD006257.
58. 58 Vajdic, CM, McDonald, SP, McCredie, MR, et al. Cancer incidence before and after kidney transplantation. JAMA 296 (2006), 2823–2831.
59. 59 Stewart, JH, Vajdic, CM, van Leeuwen, MT, et al. The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant 24 (2009), 3225–3231.
60. 60 Wong, G, Hayen, A, Chapman, JR, et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol 20 (2009), 1341–1350.
61. 61 Jørgensen, L, Heuch, I, Jenssen, T, Jacobsen, BK, Association of albuminuria and cancer incidence. J Am Soc Nephrol 19 (2008), 992–998.
62. 62 Iff, S, Craig, JC, Turner, R, et al. Reduced estimated GFR and cancer mortality. Am J Kidney Dis 63 (2014), 23–30.
63. 63 Weng, PH, Hung, KY, Huang, HL, Chen, JH, Sung, PK, Huang, KC, Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort. Clin J Am Soc Nephrol 6 (2011), 1121–1128.
64. 64 Holley, JL, Screening, diagnosis, and treatment of cancer in long-term dialysis patients. Clin J Am Soc Nephrol 2 (2007), 604–610.
65. 65 Nordio, M, Limido, A, Maggiore, U, Nichelatti, M, Postorino, M, Quintaliani, G, Survival in patients treated by long-term dialysis compared with the general population. Am J Kidney Dis 59 (2012), 819–828.
66. 66 US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients (OPTN/SRTR). 2006 OPTN/SRTR Annual Report. http://www.srtr.org/annual_Reports/archives/2006/2006_Annual_Report/default.htm, 2006 (accessed Nov 15, 2015).
67. 67 Australia and New Zealand Dialysis and Transplant Registry. 38th annual report, chapter 7: transplant waiting list. http://www.anzdata.org.au, 2016 (accessed Feb 2, 2016).
68. 68 Tonelli, M, Wiebe, N, Knoll, G, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 11 (2011), 2093–2109.
69. 69 Porter, A, Fischer, MJ, Wang, X, et al. Quality of life and outcomes in African Americans with CKD. J Am Soc Nephrol 25 (2014), 1849–1855.
70. 70 Morton, RL, Tong, A, Howard, K, Snelling, P, Webster, AC, The views of patients and carers in treatment decision making for chronic kidney disease: systematic review and thematic synthesis of qualitative studies. BMJ, 340, 2010, c112.
71. 71 Wyld, M, Morton, RL, Hayen, A, Howard, K, Webster, AC, A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med, 9, 2012, e1001307.
72. 72 Morton, RL, Webster, AC, Quality of life in chronic kidney disease. Arici, M, (eds.) Management of chronic kidney disease: a clinician's guide, 2014, Springer, Heidelberg, 489.
73. 73 Pagels, AA, Söderkvist, BK, Medin, C, Hylander, B, Heiwe, S, Health-related quality of life in different stages of chronic kidney disease and at initiation of dialysis treatment. Health Qual Life Outcomes, 10, 2012, 71.
74. 74 Soni, RK, Weisbord, SD, Unruh, ML, Health-related quality of life outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens 19 (2010), 153–159.
75. 75 Park, JI, Baek, H, Jung, HH, CKD and health-related quality of life: the Korea national health and nutrition examination survey. Am J Kidney Dis 67 (2016), 851–860.
76. 76 Breckenridge, K, Bekker, HL, Gibbons, E, et al. How to routinely collect data on patient-reported outcome and experience measures in renal registries in Europe: an expert consensus meeting. Nephrol Dial Transplant 30 (2015), 1605–1614.
77. 77 Etgen, T, Chonchol, M, Förstl, H, Sander, D, Chronic kidney disease and cognitive impairment: a systematic review and meta-analysis. Am J Nephrol 35 (2012), 474–482.
78. 78 O'Lone, E, Connors, M, Masson, P, et al. Cognition in people with end-stage kidney disease treated with hemodialysis: a systematic review and meta-analysis. Am J Kidney Dis 67 (2016), 925–935.
79. 79 Fraser, SD, Roderick, PJ, Casey, M, Taal, MW, Yuen, HM, Nutbeam, D, Prevalence and associations of limited health literacy in chronic kidney disease: a systematic review. Nephrol Dial Transplant 28 (2013), 129–137.
80. 80 Morony, S, Flynn, M, McCaffery, KJ, Jansen, J, Webster, AC, Readability of written materials for CKD patients: a systematic review. Am J Kidney Dis 65 (2015), 842–850.
81. 81 Gao, S, Manns, BJ, Culleton, BF, et al. Access to health care among status Aboriginal people with chronic kidney disease. CMAJ 179 (2008), 1007–1012.
82. 82 Cass, A, Devitt, J, Preece, C, et al. Barriers to access by Indigenous Australians to kidney transplantation: the IMPAKT study. Nephrology (Carlton) 9:suppl 4 (2004), S144–S146.
83. 83 Gao, SW, Oliver, DK, Das, N, et al. Assessment of racial disparities in chronic kidney disease stage 3 and 4 care in the department of defense health system. Clin J Am Soc Nephrol 3 (2008), 442–449.
84. 84 Hall, YN, Choi, AI, Himmelfarb, J, Chertow, GM, Bindman, AB, Homelessness and CKD: a cohort study. Clin J Am Soc Nephrol 7 (2012), 1094–1102.
85. 85 Hall, YN, Rodriguez, RA, Boyko, EJ, Chertow, GM, O'Hare, AM, Characteristics of uninsured Americans with chronic kidney disease. J Gen Intern Med 24 (2009), 917–922.
86. 86 Smart, NA, Dieberg, G, Ladhani, M, Titus, T, Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane Database Syst Rev, 6, 2014 CD007333.
87. 87 Desai, AA, Garber, AM, Chertow, GM, Rise of pay for performance: implications for care of people with chronic kidney disease. Clin J Am Soc Nephrol 2 (2007), 1087–1095.
88. 88 Karunaratne, K, Stevens, P, Irving, J, et al. The impact of pay for performance on the control of blood pressure in people with chronic kidney disease stage 3–5. Nephrol Dial Transplant 28 (2013), 2107–2116.
89. 89 Zuber, K, Davis, J, Rizk, DV, Kidney disease education one year after the Medicare Improvement of Patients and Providers Act: a survey of US nephrology practices. Am J Kidney Dis 59 (2012), 892–894.
90. 90 Moynihan, R, Glassock, R, Doust, J, Chronic kidney disease controversy: how expanding definitions are unnecessarily labelling many people as diseased. BMJ, 347, 2013, f4298.
91. 91 Matsushita, K, Mahmoodi, BK, Woodward, M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 307 (2012), 1941–1951.
92. 92 Shlipak, MG, Matsushita, K, Ärnlöv, J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 369 (2013), 932–943.
93. 93 Chadban, SJ, Briganti, EM, Kerr, PG, et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol 14:suppl 2 (2003), S131–S138.
94. 94 Levey, AS, de Jong, PE, Coresh, J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies conference report. Kidney Int 80 (2011), 17–28.
95. 95 Tangri, N, Grams, ME, Levey, AS, et al. Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis. JAMA 315 (2016), 164–174.
96. 96 Rogerson, TE, Chen, S, Kok, J, et al. Tests for latent tuberculosis in people with ESRD: a systematic review. Am J Kidney Dis 61 (2013), 33–43.
97. 97 Stacy, SR, Suarez-Cuervo, C, Berger, Z, et al. Role of troponin in patients with chronic kidney disease and suspected acute coronary syndrome: a systematic review. Ann Intern Med 161 (2014), 502–512.
98. 98 Wang, LW, Fahim, MA, Hayen, A, et al. Cardiac testing for coronary artery disease in potential kidney transplant recipients. Cochrane Database Syst Rev, 12, 2011 CD008691.
99. 99 Charytan, D, Kuntz, RE, The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 70 (2006), 2021–2030.
100. 100 Webster, AC, Cross, NB, When evidence doesn't generalise: the case of ACE inhibition. Lancet Diabetes Endocrinol 4 (2016), 290–292.
101. 101 Kearney, PM, Whelton, M, Reynolds, K, Muntner, P, Whelton, PK, He, J, Global burden of hypertension: analysis of worldwide data. Lancet 365 (2005), 217–223.
102. 102 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International 3:suppl (2013), 1–150.